ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0342

Comparison of Cortical Backscatter Ultrasound, Reference-Point Indentation and Bone Mineral Density in Discriminating Prevalent Fragility Fractures in Inflammatory Rheumatic Diseases: A Pilot Study

Edgar Wiebe1, Benjamin Kuntz2, Angela Galindo Santos3, Zhivana Boyadzhieva3, Sandra Hermann1, Burkhard Muche2, Andriko Palmowski2, Gerhard Krönke4, Ralf Schmidmaier5, Kay Raum3 and FRANK BUTTGEREIT6, 1Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, 2Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 3Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, 4Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, 5Klinikum der Universität München, Medizinische Klinik und Poliklinik IV, München, Bayern, Germany, 6Charité University Medicine Berlin, Berlin, Berlin, Germany

Meeting: ACR Convergence 2025

Keywords: Biomarkers, Fracture, osteoporosis, risk assessment, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0337–0356) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) are at elevated risk for osteoporotic fragility fractures. Standard assessment via dual-energy X-ray absorptiometry (DXA) does not fully capture fracture risk. Cortical Backscatter (CortBS) ultrasound is a radiation-free technique assessing viscoelastic and microstructural cortical bone properties and has shown high accuracy in detecting prior fractures in postmenopausal women. Bone material strength index (BMSi), derived from reference-point indentation, reflects mechanical bone properties. However, their comparative performance in fracture discrimination in iRMDs is unclear. This study aimed to evaluate the performance of CortBS in detecting prevalent fragility fractures in iRMD patients, compared to DXA and BMSi.

Methods: Consecutive iRMD patients from our outpatient osteoporosis clinic, with and without prior fragility fractures and no prior anti-osteoporotic treatment, were analyzed. CortBS was measured at the anteromedial tibia using a custom ultrasound scanner. DXA-based T-scores and BMSi (via 8 indentations) were obtained at the same visit. Fracture discrimination models for vertebral, non-vertebral, and any fragility fracture were developed using multivariate partial least squares linear discrimination analysis with Leave-One-Out Cross-Validation (PLS-LDA LOOCV). For each method, the area under the curve (AUC) of the receiver operating characteristics (ROC), sensitivity, and accuracy were calculated, with and without anthropometric data (weight, height, BMI). CortBS-BMSi correlation was assessed using PLS regression with threefold cross-validation.

Results: 97 iRMD patients (mean age 64 ± 10 years) were included: 42% with rheumatoid arthritis, 23% spondyloarthritides, and 19% connective tissue diseases. 44 patients (45%) had fragility fractures (19 vertebral, 34 non-vertebral, 9 both). Complete CortBS data were available in 40 patients (15 with fractures). CortBS showed comparable discrimination to DXA for any fracture (AUC 0.61 vs. 0.60) and non-vertebral fractures (AUC 0.68 vs. 0.69). For vertebral fractures, CortBS (AUC 0.66) outperformed both DXA (0.43) and BMSi (0.45), though small sample size limits interpretation. Adding anthropometric data improved prediction for all tools (CortBS AUC 0.73, DXA 0.75, BMSi 0.62). No significant correlation was found between CortBS and BMSi (R² = 0.05, p = 0.18).

Conclusion: CortBS demonstrated fracture discrimination comparable to DXA and even superior performance for vertebral fractures. In contrast, BMSi showed limited discriminatory ability. As a radiation-free and accessible technique, CortBS holds promise for improving fracture risk assessment in iRMDs. Larger and longitudinal studies are needed to evaluate whether CortBS can enhance fracture prediction by capturing cortical porosity and structural bone properties.

Supporting image 1Figure 1: ROC-AUC with 5-fold cross-validation for any (left), non-vertebral (center) and vertebral (right) fragility fractures for DXA, BMSi and CortBS. AP (anthropometric data: weight, height, body mass index)

Supporting image 2Figure 2: Predictions of aBMD at spine (A), femur neck (B), and total femur (C) based on ultrasound backscatter and anthropometric parameters using multivariate PLS regression Spearman correlation


Disclosures: E. Wiebe: Sobi, 6; B. Kuntz: None; A. Galindo Santos: None; Z. Boyadzhieva: None; S. Hermann: None; B. Muche: AbbVie/Abbott, 6, Amgen, 6, Celltrion, 6, Theramex, 6, UCB, 6; A. Palmowski: Novartis, 1; G. Krönke: None; R. Schmidmaier: None; K. Raum: None; F. BUTTGEREIT: Abbvie, 2, 5, 6, Biogen, 5, 6, Eli Lilly, 5, 6, Galapagos, 5, 6, grant support, consultancy fees, honoraria and travel expenses from Abbvie, Pfizer, Gruenenthal, and Horizon Therapeutics, all unrelated, 12, grant support, consultancy fees, honoraria and travel expenses from Abbvie, Pfizer, Gruenenthal, and Horizon Therapeutics, all unrelated, Janssen, 6, Medac, 5, 6, Novartis, 1, 6, pf, 5, 6, Roche, 6, Sanofi, 5, 6.

To cite this abstract in AMA style:

Wiebe E, Kuntz B, Galindo Santos A, Boyadzhieva Z, Hermann S, Muche B, Palmowski A, Krönke G, Schmidmaier R, Raum K, BUTTGEREIT F. Comparison of Cortical Backscatter Ultrasound, Reference-Point Indentation and Bone Mineral Density in Discriminating Prevalent Fragility Fractures in Inflammatory Rheumatic Diseases: A Pilot Study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/comparison-of-cortical-backscatter-ultrasound-reference-point-indentation-and-bone-mineral-density-in-discriminating-prevalent-fragility-fractures-in-inflammatory-rheumatic-diseases-a-pilot-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-cortical-backscatter-ultrasound-reference-point-indentation-and-bone-mineral-density-in-discriminating-prevalent-fragility-fractures-in-inflammatory-rheumatic-diseases-a-pilot-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology